Perspective Therapeutics, Inc. Share Price & Technical Analysis
CATX · $2.93 (-3.30%)
Healthcare / Medical Devices
$2.93
-3.30%
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors th…
Price chart
Seasonality
Jun has 3 positive and 2 negative years (last 5 years shown)
-26% return in Jun, 7% avg return in past 3 year Jun month.
14% return in 2026, 60% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 36% | 29% | -18% | -7% | 0% | -26% | – | – | – | – | – | – | 14% |
| 25 | 9% | -18% | -25% | 19% | 4% | 26% | 9% | -11% | 3% | -21% | -18% | 22% | 0% |
| 24 | 103% | 13% | 34% | 34% | -18% | -28% | 36% | 16% | -14% | -12% | -64% | -26% | 74% |
| 23 | 58% | -3% | 73% | -3% | -13% | 22% | -16% | -28% | -32% | -4% | 0% | 54% | 108% |
| 22 | -3% | -10% | 3% | -11% | -12% | 7% | 6% | 9% | -36% | 15% | 38% | -36% | -31% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$334.16M
P/E ratio
—
52W high
$6.16
52W low
$1.96
Volume
12,62,218
Beta
1.73
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹36,480
Abbott Laboratories Cede…
₹34,460
Eli Lilly And Company Ce…
₹30,560
Unitedhealth Group Inc C…
₹18,330
Elevance Health Inc
₹7,255
Frequently asked questions
- What is Perspective Therapeutics, Inc. share price today?
- Perspective Therapeutics, Inc. (CATX) last traded around $2.93 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CATX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CATX. Download the app for real-time alerts.
- How can I analyze Perspective Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.